{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:31Z","timestamp":1781643571505,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric Hodgkin lymphoma (PHL) is the most common lymphoreticular cancer in adolescents aged between 15-19 years. The survival of PHL is over 95% in developed countries with or without radiation therapy. Proper staging and risk stratification of PHL before initiation of treatment is fundamental for cure. Although outcomes for PHL in developed countries are excellent, survival in low-income countries remains lower. PHL is one of the WHO six indexed cancers with a target survival of &gt;60% by 2030 globally. The aim of the study was to evaluate clinicopathologic characteristics and treatment outcomes of PHL at two treatment centers in Ethiopia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Retrospective cohort study was conducted from January 1,2020 to December 29, 2024 at both Gondar and Jimma pediatric treatment centers. All children under 18 years of age were included in the study population. Data were extracted from each patient\u2019s medical chart review and entered with Epi-info to be analyzed using SPSS version 26. Overall survival (OS) and event free survival (EFS) were calculated and analyzed using Kaplan-Meier estimates. P-value less than 0.05 was considered statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 70 pediatric HL patients. The median age was 8.5 years (range: 4-18 years) and 77.1% of patients were males. Cervical lymphadenopathy was the commonest clinical presentation. Nodular sclerosis was the commonest histology subtype (34.3%) followed by mixed cellularity while 27% had uncategorized histology. Overall, 54.3% of patients had localized (stage I and II) and 45.7% of patients had advanced disease (stage III and IV) at initial staging. Adriamycin, Bleomycin, Vincristine, Etoposide, Prednisolone and Cyclophosphamide (ABVE-PC) was the commonest chemotherapy regimen used in our cohort (61.4%). Only 10% (7) of patients received radiation therapy all from the intermediate to high-risk group. In our study, the 3-year EFS and OS rate of pediatric HL was 85.7% and 98.6% accounting abandonment as censored. Treatment abandonment remains the challenge for cure in our cohort accounting about 31% to be censored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study showed that there was a trend towards earlier age at diagnosis of pediatric HL consistent with data from other developing countries. The treatment outcomes were good enough for newly opened centers in low-income countries with almost omission of radiotherapy, but treatment abandonment remains the challenge for cure as well affects the survival analysis in our cohorts. The treatment protocols used in this study surpassed the WHO indexed pediatric cancer survival target by 2030.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-026-06743-4","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:36:57Z","timestamp":1774406217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathologic patterns and treatment outcomes of pediatric classic hodgkin lymphoma in Ethiopian newly opened cancer treatment centers"],"prefix":"10.1186","volume":"26","author":[{"given":"Degalem Tilahun","family":"Worku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diriba Fufa","family":"Hordofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalew Melkamu","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negasa Tesema","family":"Keneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zufan Yiheyis","family":"Abriham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta Ayalew","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"3","key":"6743_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7196\/SAJCH.2020.v14i3.01723","volume":"14","author":"F Traore","year":"2020","unstructured":"Traore F, Akonde FD, Togo B, Moreira AC, Rakotomahefa N, Pondy A, et al. Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: a report from the French-African Paediatric Oncology Group (GFAOP). South Afr J Child Health. 2020;14(3):155\u201360.","journal-title":"South Afr J Child Health"},{"issue":"5","key":"6743_CR2","doi-asserted-by":"publisher","first-page":"e29601","DOI":"10.1002\/pbc.29601","volume":"69","author":"S de Armas","year":"2022","unstructured":"de Armas S, Huertas-Ayala C, Chan RY, Chi YY, Huh WW, Termuhlen A, et al. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE\u2010PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. Pediatr Blood Cancer. 2022;69(5):e29601.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"6743_CR3","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","volume":"9","author":"JM Kahn","year":"2022","unstructured":"Kahn JM, Pei Q, Friedman DL, Kaplan J, Keller FG, Hodgson D, et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children\u2019s oncology group trials. Lancet Haematol. 2022;9(1):e49\u201357.","journal-title":"Lancet Haematol"},{"issue":"10","key":"6743_CR4","first-page":"2051","volume":"114","author":"CL Schwartz","year":"2009","unstructured":"Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-and high-risk Hodgkin lymphoma: the results of P9425. Blood. J Am Soc Hematol. 2009;114(10):2051\u20139.","journal-title":"J Am Soc Hematol"},{"issue":"3","key":"6743_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3857\/roj.2020.00346","volume":"38","author":"KJ Song","year":"2020","unstructured":"Song KJ, Park J-h, Im HJ, Do Ahn S. Survival and long-term toxicities of pediatric Hodgkin lymphoma after combined modality treatment: a single institute experience. Radiation Oncol J. 2020;38(3):198.","journal-title":"Radiation Oncol J"},{"issue":"3","key":"6743_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5045\/br.2019.54.3.210","volume":"54","author":"YL Boo","year":"2019","unstructured":"Boo YL, Ting HSY, Yap DFS, Toh SG, Lim SM. Clinical features and treatment outcomes of Hodgkin lymphoma: A retrospective review in a Malaysian tertiary hospital. Blood Res. 2019;54(3):210\u20137.","journal-title":"Blood Res"},{"key":"6743_CR7","doi-asserted-by":"publisher","first-page":"2333794X2312232","DOI":"10.1177\/2333794X231223266","volume":"11","author":"HM Kabahweza","year":"2024","unstructured":"Kabahweza HM, Spencer A. Childhood Hodgkin lymphoma in Sub-Saharan Africa: a systematic review on the effectiveness of the use of chemotherapy alone. Global Pediatr Health. 2024;11:2333794X231223266.","journal-title":"Global Pediatr Health"},{"issue":"1","key":"6743_CR8","doi-asserted-by":"publisher","first-page":"101445","DOI":"10.1016\/j.beha.2023.101445","volume":"36","author":"JA Belsky","year":"2023","unstructured":"Belsky JA, Hochberg J, Giulino-Roth L. Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults. Best Pract Res Clin Haematol. 2023;36(1):101445.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"6743_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","volume":"15","author":"RT Hoppe","year":"2017","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(5):608\u201338.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"6743_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/0973-029X.294653","volume":"24","author":"RM Nirmal","year":"2020","unstructured":"Nirmal RM. Diagnosis of malignant lymphoma\u2013An overview. J Oral Maxillofacial Pathol. 2020;24(2):195\u20139.","journal-title":"J Oral Maxillofacial Pathol"},{"issue":"4","key":"6743_CR11","first-page":"1505","volume":"101","author":"I Schwering","year":"2003","unstructured":"Schwering I, Br\u00e4uninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, et al. Loss of the B-lineage\u2013specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood J Am Soc Hematol. 2003;101(4):1505\u201312.","journal-title":"Blood J Am Soc Hematol"},{"issue":"20","key":"6743_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"S1","key":"6743_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5045\/br.2022.2022037","volume":"57","author":"J Cho","year":"2022","unstructured":"Cho J. Basic immunohistochemistry for lymphoma diagnosis. Blood Res. 2022;57(S1):55\u201361.","journal-title":"Blood Res"},{"key":"6743_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1200\/GO.20.00088","volume":"6","author":"RJ DeBoer","year":"2020","unstructured":"DeBoer RJ, Shyirambere C, Driscoll CD, Butera Y, Paciorek A, Ruhangaza D, et al. Treatment of Hodgkin lymphoma with ABVD chemotherapy in rural Rwanda: A model for cancer care delivery implementation. JCO Global Oncol. 2020;6:1093\u2013102.","journal-title":"JCO Global Oncol"},{"issue":"22","key":"6743_CR15","first-page":"2452","volume":"126","author":"KM Kelly","year":"2015","unstructured":"Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood. J Am Soc Hematol. 2015;126(22):2452\u20138.","journal-title":"J Am Soc Hematol"},{"issue":"1","key":"6743_CR16","first-page":"215868","volume":"2012","author":"A Pourtsidis","year":"2012","unstructured":"Pourtsidis A, Doganis D, Baka M, Bouhoutsou D, Varvoutsi M, Synodinou M, et al. Successful Treatment in Children with Hodgkin Lymphoma in Greece; A 20-Year Experience in a Single Institution. Lymphoma. 2012;2012(1):215868.","journal-title":"Lymphoma"},{"key":"6743_CR17","unstructured":"Organization WH. CureAll framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives. CureAll framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives2021."},{"issue":"32","key":"6743_CR18","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","volume":"32","author":"DL Friedman","year":"2014","unstructured":"Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"6743_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijrobp.2021.07.1716","volume":"112","author":"MD Hall","year":"2022","unstructured":"Hall MD, Terezakis SA, Lucas JT, Gallop-Evans E, Dieckmann K, Constine LS, et al. Radiation therapy across pediatric Hodgkin lymphoma research group protocols: a report from the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group. Int J Radiation Oncology* Biology* Phys. 2022;112(2):317\u201334.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"3","key":"6743_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","volume":"24","author":"C Mauz-K\u00f6rholz","year":"2023","unstructured":"Mauz-K\u00f6rholz C, Landman-Parker J, Fern\u00e1ndez-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, et al. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. Lancet Oncol. 2023;24(3):252\u201361.","journal-title":"Lancet Oncol"},{"key":"6743_CR21","unstructured":"Program S. Cancer incidence and survival among children and adolescents: United States SEER program, 1975\u20131995. National Cancer Institute; 1999."},{"issue":"7","key":"6743_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1200\/JCO.2012.43.5958","volume":"31","author":"S Saarinen","year":"2013","unstructured":"Saarinen S, Pukkala E, Vahteristo P, M\u00e4kinen MJ, Franssila K, Aaltonen LA. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2013;31(7):938\u201343.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6743_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s43046-023-00189-w","volume":"35","author":"N Ali","year":"2023","unstructured":"Ali N, Mansour M, Khalil E, Ebeid E. Outcome and prognostic factors of pediatric patients with Hodgkin lymphoma: a single-center experience. J Egypt Natl Cancer Inst. 2023;35(1):29.","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"12","key":"6743_CR24","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.1999.17.12.3736","volume":"17","author":"R Schellong Gn, P\u00f6tter","year":"1999","unstructured":"Schellong Gn, P\u00f6tter R, Br\u00e4mswig W Jr, Prott F-J, D\u00f6rffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin\u2019s disease: the German-Austrian multicenter trial DAL-HD-90. J Clin Oncol. 1999;17(12):3736\u201344.","journal-title":"J Clin Oncol"},{"issue":"15","key":"6743_CR25","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1097\/MD.0000000000000670","volume":"94","author":"LM Sherief","year":"2015","unstructured":"Sherief LM, Elsafy UR, Abdelkhalek ER, Kamal NM, Elbehedy R, Hassan TH, et al. Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country. Medicine. 2015;94(15):e670.","journal-title":"Medicine"},{"issue":"3","key":"6743_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MPH.0b013e318271f587","volume":"35","author":"A Trehan","year":"2013","unstructured":"Trehan A, Singla S, Marwaha RK, Bansal D, Srinivasan R. Hodgkin lymphoma in children: experience in a tertiary care centre in India. J Pediatr Hematol Oncol. 2013;35(3):174\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"key":"6743_CR27","unstructured":"Uysal KM, \u00c7et\u0131ng\u00f6z R, G\u00fcne\u015f D. Clinical characteristics and therapy outcome of pediatric Hodgkin\u2019s lymphoma-a single centre experience from the west part of Turkey. Turkish J Cancer. 2007;37(3)."},{"issue":"3","key":"6743_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/jcp.53.3.182","volume":"53","author":"M Engel","year":"2000","unstructured":"Engel M, Essop M, Close P, Hartley P, Pallesen G, Sinclair-Smith C. Improved prognosis of Epstein-Barr virus associated childhood Hodgkin\u2019s lymphoma: study of 47 South African cases. J Clin Pathol. 2000;53(3):182\u20136.","journal-title":"J Clin Pathol"},{"issue":"2","key":"6743_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/10428190802663205","volume":"50","author":"DC Stefan","year":"2009","unstructured":"Stefan DC, Stones D. How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma. 2009;50(2):196\u20139.","journal-title":"Leuk Lymphoma"},{"key":"6743_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/oxfordjournals.epirev.a036276","volume":"6","author":"S Grufferman","year":"1984","unstructured":"Grufferman S, Delzell E. Epidemiology of Hodgkin\u2019s disease. Epidemiol Rev. 1984;6:76\u2013106.","journal-title":"Epidemiol Rev"},{"issue":"5","key":"6743_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/JGO.2016.005314","volume":"3","author":"V Radhakrishnan","year":"2017","unstructured":"Radhakrishnan V, Dhanushkodi M, Ganesan TS, Ganesan P, Sundersingh S, Selvaluxmy G, et al. Pediatric Hodgkin lymphoma treated at Cancer institute, Chennai, India: Long-term outcome. J Global Oncol. 2017;3(5):545\u201354.","journal-title":"J Global Oncol"},{"issue":"2","key":"6743_CR32","first-page":"69","volume":"5","author":"E Khan","year":"2024","unstructured":"Khan E, Begum F, Karim S, Akter M, Yasmin F, Soma S, et al. Clinico-pathological profile and Treatment Outcome of Paediatric Hodgkin Lymphoma in Bangladesh: A Single Centre Experience. Cancer J Bangladesh. 2024;5(2):69\u201374.","journal-title":"Cancer J Bangladesh"},{"issue":"1","key":"6743_CR33","doi-asserted-by":"publisher","first-page":"e30712","DOI":"10.1002\/pbc.30712","volume":"71","author":"J Geel","year":"2024","unstructured":"Geel J, Van Zyl A, Plessis Jd, Hendricks M, Goga Y, Carr A, et al. Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa. Pediatr Blood Cancer. 2024;71(1):e30712.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"6743_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3109\/08880018.2013.823471","volume":"30","author":"A Pourtsidis","year":"2013","unstructured":"Pourtsidis A, Doganis D, Baka M, Bouhoutsou D, Varvoutsi M, Synodinou M, et al. Differences between younger and older patients with childhood Hodgkin lymphoma. Pediatr Hematol Oncol. 2013;30(6):532\u20136.","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"6743_CR35","first-page":"904","volume":"26","author":"M Faizan","year":"2016","unstructured":"Faizan M, Taj MM, Anwar S, Asghar N, Ahmad A, Lancaster D, et al. Comparison of presentation and outcome in 100 pediatric Hodgkin lymphoma patients treated at Children Hospital, Lahore, Pakistan and Royal Marsden Hospital, UK. J Coll Physicians Surg Pak. 2016;26(11):904\u20137.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"14","key":"6743_CR36","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa023141","volume":"349","author":"H Hjalgrim","year":"2003","unstructured":"Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang J-S, et al. Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis. N Engl J Med. 2003;349(14):1324\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"6743_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","volume":"70","author":"SL Glaser","year":"1997","unstructured":"Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, et al. Epstein-Barr virus\u2010associated Hodgkin\u2019s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375\u201382.","journal-title":"Int J Cancer"},{"issue":"1","key":"6743_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/(SICI)1096-911X(199901)32:1<18::AID-MPO5>3.0.CO;2-S","volume":"32","author":"A Cavdar","year":"1999","unstructured":"Cavdar A, Pamir A, G\u00f6zda\u015foglu S, Babacan E, Yavuz G, \u00dcnal E, et al. Hodgkin disease in children: Clinicoepidemiologic and viral (Epstein-Barr virus) analyses. Med Pediatr Oncology: Official J SIOP\u2014International Soc Pediatr Oncol (Societ\u00e9 Int d\u2019Oncologie P\u00e9diatrique. 1999;32(1):18\u201324.","journal-title":"Med Pediatr Oncology: Official J SIOP\u2014International Soc Pediatr Oncol (Societ\u00e9 Int d\u2019Oncologie P\u00e9diatrique"},{"issue":"2","key":"6743_CR39","first-page":"141","volume":"43","author":"V Dinand","year":"2006","unstructured":"Dinand V, Arya LS. Epidemiology of childhood Hodgkin\u2019s disease: is it different in developing countries? Indian Pediatr. 2006;43(2):141.","journal-title":"Indian Pediatr"},{"issue":"13","key":"6743_CR40","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.ejca.2006.05.012","volume":"42","author":"J Clavel","year":"2006","unstructured":"Clavel J, Steliarova-Foucher E, Berger C, Danon S, Valerianova Z. Hodgkin\u2019s disease incidence and survival in European children and adolescents (1978\u20131997): report from the Automated Cancer Information System project. Eur J Cancer. 2006;42(13):2037\u201349.","journal-title":"Eur J Cancer"},{"issue":"10","key":"6743_CR41","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1200\/JCO.1994.12.10.2160","volume":"12","author":"SP Hunger","year":"1994","unstructured":"Hunger SP, Link MP, Donaldson SS. ABVD\/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin\u2019s disease: the Stanford experience. J Clin Oncol. 1994;12(10):2160\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6743_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pbc.20157","volume":"46","author":"LS Arya","year":"2006","unstructured":"Arya LS, Dinand V, Thavaraj V, Bakhshi S, Dawar R, Rath GK, et al. Hodgkin\u2019s disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer. 2006;46(1):26\u201334.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"6743_CR43","first-page":"327237","volume":"2011","author":"B Togo","year":"2011","unstructured":"Togo B, Traor\u00e9 F, Togo A, Traor\u00e9 C, Dumke K, Diawara M, et al. Hodgkin Lymphoma at the Paediatric Oncology Unit of Gabriel Tour\u00e9 Teaching Hospital, Bamako, Mali: 5-Year Experience. Adv Hematol. 2011;2011(1):327237.","journal-title":"Adv Hematol"},{"key":"6743_CR44","volume-title":"Principles and practice of pediatric oncology","author":"MA Smith","year":"2002","unstructured":"Smith MA, Ries L, Gurney JG, Bondy ML, Plon SE, Malkin D, et al. Principles and practice of pediatric oncology. Edited by: Pizzo PAPoplack GD; 2002."},{"issue":"4","key":"6743_CR45","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/MOH.0b013e328302c9d8","volume":"15","author":"NL Bartlett","year":"2008","unstructured":"Bartlett NL. Modern treatment of Hodgkin lymphoma. Curr Opin Hematol. 2008;15(4):408\u201314.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"6743_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2006.08.036","volume":"43","author":"V Dinand","year":"2007","unstructured":"Dinand V, Dawar R, Arya LS, Unni R, Mohanty B, Singh R. Hodgkin\u2019s lymphoma in Indian children: prevalence and significance of Epstein\u2013Barr virus detection in Hodgkin\u2019s and Reed\u2013Sternberg cells. Eur J Cancer. 2007;43(1):161\u20138.","journal-title":"Eur J Cancer"},{"issue":"1","key":"6743_CR47","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1038\/s41598-025-90493-3","volume":"15","author":"YM Molla","year":"2025","unstructured":"Molla YM, Shad A, Wali R, Yimer MA. The magnitude and associated factors of childhood cancer treatment abandonment at the university of Gondar comprehensive specialized hospital, Ethiopia. Sci Rep. 2025;15(1):10534.","journal-title":"Sci Rep"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-06743-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06743-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06743-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:48:21Z","timestamp":1781642901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-06743-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6743"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-06743-4","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance obtained from University of Gondar College of Medicine and health science with reference number SOM\/1675\/2024 after proposal was submitted and reviewed by the ethical committee. The study was conducted adhering to Helsinki\u2019s declaration procedures for human subjects. The need for consent to participate was waived by the university of Gondar College of medicine and health science ethics committee and deemed unnecessary according to national regulations because it was a retrospective study, and the data extracted from the files\/ charts were analyzed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}